BBIO
BridgeBio Pharma Inc
67.00$
+1.2%
vs. previous close
Closing price · As of: Oct 6, 2026
Statements
Cash Flow
BridgeBio Pharma Inc (BBIO) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -223 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -18 | -34 | -38 | -46 | -59 | -68 | -50 | -76 | -84 | -88 | -132 | -96 | -151 | -92 | -122 | -134 | -161 | -30 | -135 | -93 | -144 | -113 | -145 | -125 | -220 | 75 | -181 | -195 | -199 | -81 | -110 | -56 | -197 | -223 | -587 | |
| 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.4 | -0.6 | 0.5 | 1.5 | -1.0 | 3.1 | 0.6 | 2.7 | 0.3 | 1.5 | 1.9 | 1.6 | 1.6 | 1.7 | 1.6 | 1.6 | 1.6 | 1.6 | 1.6 | 1.6 | 1.5 | 1.4 | 1.3 | 1.3 | 1.4 | 1.5 | 1.8 | 1.9 | 6.6 | |
| 0.8 | 1.0 | 1.2 | 3.1 | 2.2 | 3.3 | 5.8 | 10 | 10 | 18 | 18 | 12 | 34 | 30 | 16 | 20 | 24 | 28 | 17 | 22 | 22 | 27 | 23 | 37 | 17 | 21 | 27 | 30 | 26 | 37 | 35 | 35 | 33 | 44 | 147 | |
| 10 | -6.3 | -9.2 | – | 2.8 | 0.5 | 13 | 1.8 | 0.2 | 12 | 13 | 5.6 | 39 | 28 | 17 | 23 | 44 | -55 | 18 | 18 | 22 | 29 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 6.1 | -1.2 | 2.2 | 15 | -0.7 | -3.0 | -3.3 | -3.9 | 7.7 | 22 | -29 | 15 | -15 | -26 | 16 | 21 | -10 | 33 | -6.9 | 12 | -32 | 14 | 1.3 | 22 | -225 | 246 | -2.1 | 13 | -116 | 19 | -3.9 | 50 | -125 | -27 | -107 | |
| 15 | 1.7 | 0.6 | 0.7 | 2.4 | 0.6 | 0.4 | 1.7 | 4.5 | 0.3 | 0.5 | 2.1 | 2.0 | 2.3 | 41 | 2.5 | 0.9 | 3.9 | 0.8 | 0.8 | 0.0 | 0.4 | 0.4 | 0.4 | 1.5 | 2.4 | 1.7 | 3.2 | 1.6 | 5.1 | 0.5 | 4.5 | 0.1 | 0.4 | 5.5 | |
| -15 | -1.7 | -0.6 | -3.6 | -2.4 | -0.6 | -197 | 22 | 38 | -129 | -45 | 83 | -282 | -84 | 59 | 22 | 139 | 150 | 147 | 18 | 12 | 4.1 | 38 | -0.1 | 23 | 3.0 | 38 | -3.2 | -1.6 | -13 | 4.5 | -14 | -43 | 18 | -34 | |
| – | – | – | – | 1.0 | 0.0 | 0.0 | 1.0 | 0.0 | 0.0 | 0.0 | 0.0 | – | – | – | 111 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | 431 | 0.1 | 0.5 | 390 | 369 | -75 | 0.0 | -0.2 | -0.5 | -51 | -7.6 | -144 | -2.3 | -0.1 | -0.4 | -0.6 | 1.1 | -0.5 | -1.2 | -2.6 | -2.6 | -2.9 | -1.7 | -1.4 | -1.4 | -50 | -2.0 | 3.8 | -5.5 | -83 | -128 | -212 | |
| 3.5 | 34 | -0.6 | – | 20 | 20 | 17 | 17 | 550 | 748 | 748 | 748 | 731 | 6.9 | 325 | 325 | -1.1 | -20 | – | 1.1 | – | – | – | – | – | – | 0.0 | 500 | 116 | 300 | -300 | 0.0 | 633 | 0.0 | 333 | |
| 16 | 213 | -1.7 | 274 | -1.7 | -10.0 | 368 | 3.8 | 439 | 0.7 | 2.8 | 4.5 | 548 | 83 | -135 | 325 | -0.2 | -21 | 1.4 | 6.4 | 150 | -1.2 | 307 | -4.5 | 280 | -5.7 | 0.7 | 474 | 60 | 302 | -0.9 | -2.8 | 550 | -299 | 247 | |
| -17 | 178 | -41 | 224 | -63 | -79 | 120 | -50 | 393 | -216 | -174 | -8.7 | 115 | -93 | -198 | 213 | -22 | 98 | 13 | -69 | 18 | -110 | 199 | -129 | 83 | 72 | -142 | 275 | -141 | 208 | -106 | -72 | 310 | -504 | -373 | |
| -33 | -36 | -39 | -47 | -62 | -69 | -50 | -78 | -88 | -88 | -132 | -98 | -153 | -94 | -163 | -136 | -161 | -34 | -136 | -94 | -144 | -114 | -146 | -125 | -221 | 72 | -182 | -199 | -201 | -86 | -110 | -61 | -197 | -224 | -592 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.